32299471|t|alpha-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
32299471|a|BACKGROUND: Studies link c-Abl activation with the accumulation of pathogenic alpha-synuclein (alphaS) and neurodegeneration in Parkinson's disease (PD). Currently, c-Abl, a tyrosine kinase activated by cellular stress, is thought to promote alphaS pathology by either directly phosphorylating alphaS or by causing autophagy deficits. METHODS: alphaS overexpressing transgenic (Tg) mice were used in this study. A53T Tg mice that express high levels of human mutant A53TalphaS under the control of prion protein promoter. Two different approaches were used in this study. Natural aging and seeding model of synucleinopathy. In seeding model, intracortical/intrastriatal (IC/IS) stereotaxic injection of toxic lysates was done using tissue lysates from end-stage symptomatic mice. In this study, nilotinib and pifithrin-alpha was used as a c-Abl and p53 inhibitor, respectively. Both Tg and non-transgenic (nTg) mice from each group were subjected to nilotinib (10 mg/kg) or vehicle (DMSO) treatment. Frozen brain tissues from PD and control human cases were analyzed. In vitro cells study was implied for c-Abl/p53 genetic manipulation to uncover signal transduction. RESULTS: Herein, we show that the pathologic effects of c-Abl in PD also involve activation of p53, as c-Abl activation in a transgenic mouse model of alpha-synucleinopathy (TgA53T) and human PD cases are associated with the increased p53 activation. Significantly, active p53 in TgA53T neurons accumulates in the cytosol, which may lead to inhibition of autophagy. Thus, we hypothesized that c-Abl-dependent p53 activation contributes to autophagy impairment in alpha-synucleinopathy. In support of the hypothesis, we show that c-Abl activation is sufficient to inhibit autophagy in p53-dependent manner. Moreover, inhibition of either c-Abl, using nilotinib, or p53, using pifithrin-alpha, was sufficient to increase autophagic flux in neuronal cells by inducing phosphorylation of AMP-activated kinase (AMPK), ULK1 activation, and down-regulation of mTORC1 signaling. Finally, we show that pharmacological attenuation of c-Abl activity by nilotinib treatment in the TgA53T mouse model reduces activation of p53, stimulates autophagy, decreases accumulation alphaS pathology, and delays disease onset. CONCLUSION: Collectively, our data show that c-Abl activation by alpha-synucleinopathy causes p53 dependent autophagy deficits and both c-Abl and p53 represent therapeutic target for PD.
32299471	0	21	alpha-Synucleinopathy	Disease	MESH:D000080874
32299471	33	38	c-Abl	Gene	11350
32299471	57	60	p53	Gene	22060
32299471	118	123	c-Abl	Gene	11350
32299471	171	186	alpha-synuclein	Gene	6622
32299471	188	194	alphaS	Gene	112935892
32299471	200	217	neurodegeneration	Disease	MESH:D019636
32299471	221	240	Parkinson's disease	Disease	MESH:D010300
32299471	242	244	PD	Disease	MESH:D010300
32299471	258	263	c-Abl	Gene	25
32299471	267	282	tyrosine kinase	Gene	7294
32299471	335	341	alphaS	Gene	112935892
32299471	387	393	alphaS	Gene	112935892
32299471	437	443	alphaS	Gene	112935892
32299471	475	479	mice	Species	10090
32299471	505	509	A53T	ProteinMutation	tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:9606;CA#:257068
32299471	513	517	mice	Species	10090
32299471	546	551	human	Species	9606
32299471	591	604	prion protein	Gene	19122
32299471	700	715	synucleinopathy	Disease	MESH:D000080874
32299471	867	871	mice	Species	10090
32299471	888	897	nilotinib	Chemical	MESH:C498826
32299471	902	917	pifithrin-alpha	Chemical	MESH:C121565
32299471	927	929	as	Gene	112935892
32299471	932	937	c-Abl	Gene	11350
32299471	942	945	p53	Gene	7157
32299471	1004	1008	mice	Species	10090
32299471	1043	1052	nilotinib	Chemical	MESH:C498826
32299471	1076	1080	DMSO	Chemical	MESH:D004121
32299471	1119	1121	PD	Disease	MESH:D010300
32299471	1134	1139	human	Species	9606
32299471	1198	1203	c-Abl	Gene	11350
32299471	1204	1207	p53	Gene	7157
32299471	1317	1322	c-Abl	Gene	11350
32299471	1326	1328	PD	Disease	MESH:D010300
32299471	1356	1359	p53	Gene	22060
32299471	1361	1363	as	Gene	112935892
32299471	1364	1369	c-Abl	Gene	11350
32299471	1397	1402	mouse	Species	10090
32299471	1412	1433	alpha-synucleinopathy	Disease	MESH:D000080874
32299471	1437	1441	A53T	ProteinMutation	tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:9606;CA#:257068
32299471	1447	1452	human	Species	9606
32299471	1453	1455	PD	Disease	MESH:D010300
32299471	1496	1499	p53	Gene	22060
32299471	1534	1537	p53	Gene	7157
32299471	1654	1659	c-Abl	Gene	11350
32299471	1670	1673	p53	Gene	7157
32299471	1724	1745	alpha-synucleinopathy	Disease	MESH:D000080874
32299471	1790	1795	c-Abl	Gene	11350
32299471	1845	1848	p53	Gene	22060
32299471	1898	1903	c-Abl	Gene	11350
32299471	1911	1920	nilotinib	Chemical	MESH:C498826
32299471	1925	1928	p53	Gene	7157
32299471	1936	1951	pifithrin-alpha	Chemical	MESH:C121565
32299471	2074	2078	ULK1	Gene	22241
32299471	2185	2190	c-Abl	Gene	11350
32299471	2203	2212	nilotinib	Chemical	MESH:C498826
32299471	2237	2242	mouse	Species	10090
32299471	2271	2274	p53	Gene	22060
32299471	2321	2327	alphaS	Gene	112935892
32299471	2410	2415	c-Abl	Gene	11350
32299471	2430	2451	alpha-synucleinopathy	Disease	MESH:D000080874
32299471	2459	2462	p53	Gene	22060
32299471	2501	2506	c-Abl	Gene	11350
32299471	2511	2514	p53	Gene	22060
32299471	2548	2550	PD	Disease	MESH:D010300
32299471	Negative_Correlation	MESH:C121565	7157
32299471	Negative_Correlation	MESH:C121565	112935892
32299471	Association	MESH:D000080874	22060
32299471	Association	MESH:D010300	6622
32299471	Negative_Correlation	MESH:C498826	11350
32299471	Association	22241	7157
32299471	Association	112935892	25
32299471	Positive_Correlation	MESH:C498826	22241
32299471	Association	MESH:D010300	11350
32299471	Association	112935892	11350
32299471	Negative_Correlation	MESH:C121565	11350
32299471	Association	MESH:D010300	22060
32299471	Positive_Correlation	11350	6622
32299471	Association	MESH:D019636	11350
32299471	Association	MESH:D000080874	11350
32299471	Association	11350	7157
32299471	Positive_Correlation	11350	22060
32299471	Association	MESH:D000080874	7157
32299471	Negative_Correlation	MESH:C498826	7157
32299471	Positive_Correlation	MESH:C121565	22241
32299471	Association	MESH:D010300	112935892

